Validation and Utility of a Non-Invasive 2-Gene Molecular Assay for Cutaneous Melanoma

Laura K. Ferris, MD, PhD, Burkhard Jansen, MD, Jonathan Ho, MD, Klaus J. Busam, MD, Kenneth Goss, MD, Doyle D. Hansen, MD, John P. Alsobrook II, PhD, Zuxu Yao, PhD, and Pedram Gerami, MD

**Background:** To minimize the number of melanomas missed, clinicians generally biopsy 10 or more benign nevi for each melanoma. This low specificity results in many unnecessary procedures for patients.

**Approach:** We have previously reported on a pigmented lesion assay (PLA) concept where samples are obtained non-invasively via adhesive patch sampling. We here evaluated the performance of a novel and optimized gene signature using two genes, *LINC* and *PRAME*, to distinguish benign nevi from melanoma in prospectively collected samples (n=319). In addition, using a web based multi-reader multi-case study, 45 dermatologists each evaluated 60 representative clinical and dermatoscopic images of clinically atypical pigmented lesions from the validation study, first without and then with PLA data.

**Results:** The PLA is a sensitive and specific method for detection of cutaneous melanoma (AUC 0.91, NPV>99%, sensitivity 92%, specificity 64%). Dermatologists who incorporated the PLA into their biopsy decision improved their relative biopsy specificity by 77.3 % (p<0.001), and improved biopsy sensitivity from 95.0% to 98.6% (p=0.01), compared to their decision without the PLA.

**Innovation and Relevance:** The PLA is a non-invasive tool that enables dermatologists to significantly improve biopsy specificity, thus removing fewer benign nevi, while maintaining or improving sensitivity.
Presenting Author:
Laura Ferris, MD, PhD
Department of Dermatology, University of Pittsburgh
3601 Fifth Avenue, Fifth Floor, Pittsburgh, PA 15238
Phone: 412-647-2013
Email: ferrislk@upmc.edu

*DermTech Inc, La Jolla, CA
+Memorial Sloan Kettering Cancer Center, New York, NY
&Skin Surgery Medical Group, San Diego, CA
’East County Dermatology Medical Group, El Cajon, CA
’Department of Dermatology, Northwestern University, Chicago, IL

About DermTech:
DermTech is a molecular diagnostics company focused on developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA laboratory located at the company’s La Jolla, CA headquarters. DermTech’s technology allows the analysis of skin samples biopsied non-invasively using an adhesive patch rather than a scalpel. DermTech provides highly accurate, objective information to the physicians to improve patient care through advanced molecular pathology gene expression information.